One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term ...

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

Since there's no information about Carvykti (cilta-cel) in the 10-K, I've opened Legend's Form 20-F. According to it, ...

Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts. ・Pricing updates for major therapies ...

The iShares Biotechnology ETF (NYSE: IBB) has risen for six straight months, notching its longest winning streak since 2012.

Clinuvel founder Philippe Wolgen has taken an unorthodox approach to biotech, from his recruitment philosophy to R&D strategy ...

Bay Area startup ASC Therapeutics filed for bankruptcy on Wednesday, marking the end of the line for the gene and cell ...

Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, ...

Jyong Biotech advances plant-derived carotenoid drugs with MCS-2 for BPH and early programs like MCS-8 showing signals as ...

The team at GV manages some $10 billion that the tech giant has set aside for early-stage companies. Schenkein’s group ...